Drug intelligence / Profile preview

AP-PA03

Development stage: Preclinical
Lead developer: Armata Pharmaceuticals
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Inhalation

Overview

**AP-PA03** is Armata Pharmaceuticals' preclinical, pathogen-specific five-bacteriophage cocktail being developed for acute hospitalized pneumonia caused by *Pseudomonas aeruginosa*, including potential use in ventilator-associated pneumonia and other severe acute respiratory infections involving multidrug-resistant *P. aeruginosa*. The product is designed to use multiple bacteriophages to selectively infect and kill the bacterial pathogen while avoiding broad-spectrum antibacterial effects on non-target microbiota. ([armatapharma.com](https://www.armatapharma.com/pipeline/ap-pa02/))

Targets

P. aeruginosa (Pseudomonas aeruginosa)

Beyond the preview

Go deeper on AP-PA03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP-PA03.

Explore the full profile